Who gets genomic testing for breast cancer recurrence risk?

Public Health Genomics

Volumn 16, Issue 5, 2013, Pages 215-222

  DeFrank, J T ^a   Salz, T ^d   Reeder Hayes, K ^b,c   Brewer, N T ^a,b  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Genomics; Oncology; Oncotype DX; Patient decision making; Risk recurrence

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENCE RISK; TUMOR VOLUME;

EID: 84885621404     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000353518     Document Type: Article

References (22)

1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
2. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728.
3. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
4. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-1834.
5. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8:R25.
6. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr., Wickerham DL, Wolmark N: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
7. Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ: Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012; 104: 1068-1079.
8. O'Neill SC, Brewer NT, Lillie SE, Morrill EF, Dees EC, Carey LA, Rimer BK: Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol 2007; 25: 4628-4634.
9. Schwartz LM, Woloshin S, Black WC, Welch HG: The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997; 127: 966-972.
10. Morris NS, MacLean CD, Chew LD, Littenberg B: The Single Item Literacy Screener: evaluation of a brief instrument to identify limited reading ability. BMC Fam Pract 2006; 7: 21.
11. Lerman C, Daly M, Masny A, Balshem A: Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994; 12: 843-850.
12. Degner LF, Sloan JA, Venkatesh P: The Control Preferences Scale. Can J Nurs Res 1997; 29: 21-43.
13. Bruera E, Sweeney C, Calder K, Palmer L, Benisch-Tolley S: Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 2001; 19: 2883-2885.
14. Grunfeld EA, Maher EJ, Browne S, Ward P, Young T, Vivat B, Walker G, Wilson C, Potts HW, Westcombe AM, Richards MA, Ramirez AJ: Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol 2006; 24: 1090-1098.
15. Tzeng JP, Mayer D, Richman AR, Lipkus I, Han PK, Valle CG, Carey LA, Brewer NT: Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 2010; 116: 1992-2000.
16. Spellman E, Sulayman N, Eggly S, Peshkin BN, Isaacs C, Schwartz MD, O'Neill SC: Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives. Psychooncology 2013, Epub ahead of print.
17. Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007; 12: 631-635.
18. DeFrank JT, Carey LA, Brewer NT: Understanding how breast cancer patients use risk information from genomic tests. J Behav Med 2012, E-pub ahead of print.
19. Frosch DL, Kaplan RM: Shared decision making in clinical medicine: past research and future directions. Am J Prev Med 1999; 17: 285-294.
20. Moonesinghe R, Jones W, Honoré PA, Truman BI, Graham G: Genomic medicine and racial/ethnic health disparities: promises, perils, and the challenges for health care and public health policy. Ethn Dis 2009; 19: 473-478.
21. Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC: Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012; 30: 2218-2226.
22. Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM: 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 2012; 118: 788-796.